Premium
Current and possible future treatment of ocular adnexal lymphomas
Author(s) -
PETTITT A
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.5265.x
Subject(s) - medicine , stage (stratigraphy) , rituximab , radiation therapy , disease , lymphoma , dermatology , chemotherapy , surgery , pathology , paleontology , biology
Purpose To review the current and possible future therapies of ocular adnexal lymphomas. Methods Ocular adnexal lymphomas represent approx. 8% of all extranodal lymphomas. The majority of these can be classified as extranodal marginal zone (MALT) lymphomas, and are usually staged as Stage IE disease. Results Recommended therapy in Stage IE tumours is low‐dose radiotherapy, while disseminated disease (>Stage IIE) is treated with chemotherapy. Although often responding to initial therapy, the MALT lymphomas tend to recur in distant extranodal sites. Few biomarkers are available to aid prediction of either recurrence or systemic dissemination, which occurs in up to 25% of patients. The ocular morbidity associated with current therapies is not insignificant, and, therefore, more effective treatment is being sought. Conclusion The newer treatment options, including rituximab and doxycyclin, will be discussed